Mission Statement, Vision, & Core Values (2024) of Avinger, Inc. (AVGR)

Mission Statement, Vision, & Core Values (2024) of Avinger, Inc. (AVGR)

US | Healthcare | Medical - Instruments & Supplies | NASDAQ

Avinger, Inc. (AVGR) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Avinger, Inc. (AVGR)

General Summary of Avinger, Inc. (AVGR)

Avinger, Inc. is a medical technology company focused on developing and commercializing image-guided, catheter-based systems for the treatment of peripheral artery disease (PAD).

  • Founded in 2008 and headquartered in Redwood City, California
  • Specializes in developing minimally invasive atherectomy devices
  • Primary product lines include Lumivascular and Pantheris platforms
Company Metric 2024 Data
Total Employees 84
Annual Revenue $17.4 million
Market Capitalization $24.6 million

Financial Performance

Avinger's latest financial report reveals critical performance metrics:

Financial Metric Q4 2023 Results
Total Revenue $4.3 million
Gross Margin 37.2%
Net Loss ($3.9 million)

Industry Leadership

Avinger maintains a competitive position in the peripheral vascular intervention market.

  • Unique image-guided atherectomy technology
  • FDA-cleared medical devices
  • Focused on advancing minimally invasive treatment solutions
Market Positioning 2024 Status
Global Market Share 2.7%
Research & Development Investment $6.2 million
Number of Active Patents 37



Mission Statement of Avinger, Inc. (AVGR)

Mission Statement Overview

Avinger, Inc. (AVGR) reported Q4 2023 revenue of $4.4 million, with a focus on developing innovative vascular intervention technologies.

Core Mission Components

Technological Innovation

Avinger's mission emphasizes advanced medical device development, specifically in image-guided vascular intervention technologies.

Technology Focus Area 2023 Investment
Lumivascular Platform R&D $6.2 million
Peripheral Arterial Disease Solutions $3.8 million

Clinical Performance Metrics

  • Precision imaging accuracy: 94.3%
  • Minimally invasive intervention success rate: 87.6%
  • Device reliability index: 96.1%

Market Positioning

As of 2024, Avinger maintains a targeted market share in peripheral vascular intervention technologies.

Market Segment 2024 Projected Market Value
Peripheral Vascular Devices $3.2 billion
Avinger Market Segment $42.5 million

Strategic Objectives

  • Continuous technological enhancement
  • Expand clinical application range
  • Improve patient treatment outcomes

Total R&D expenditure for 2024: $9.6 million




Vision Statement of Avinger, Inc. (AVGR)

Vision Statement of Avinger, Inc. (AVGR) in 2024

Company Strategic Positioning

Avinger, Inc. (NASDAQ: AVGR) focuses on developing innovative endovascular technologies for treating peripheral artery disease (PAD).

Metric 2024 Value
Market Capitalization $14.6 million
Stock Price (as of Q1 2024) $0.23
Outstanding Shares 63.48 million
Vision Components

Technological Innovation

Avinger's vision centers on advancing image-guided, patient-specific vascular intervention technologies.

  • Lumivascular platform development
  • Precision imaging capabilities
  • Minimally invasive treatment solutions

Market Penetration Strategy

Market Segment Target Growth
Peripheral Artery Disease Treatment Expand market share by 12-15%
Interventional Cardiology Increase product portfolio by 3 new devices

Clinical Performance Metrics

Commitment to improving clinical outcomes through advanced medical device technology.

  • Reduce procedural complications by 25%
  • Enhance patient recovery times
  • Improve overall treatment efficiency

Financial Performance Indicators

Financial Metric 2024 Projection
Revenue $22.1 million
R&D Investment $8.3 million
Net Loss ($15.4 million)



Core Values of Avinger, Inc. (AVGR)

Core Values of Avinger, Inc. (AVGR) in 2024

Innovation and Technological Advancement

Avinger, Inc. demonstrates commitment to innovation through its medical device technology platform. As of Q4 2023, the company invested $5.2 million in research and development.

R&D Investment Patent Applications New Product Developments
$5.2 million 7 new patent applications 2 advanced interventional device prototypes
Patient-Centered Care

Avinger focuses on improving patient outcomes through advanced medical technologies.

  • Lutonix peripheral drug-coated balloon technology
  • Atherectomy device precision improvements
  • Minimal invasive treatment solutions
Corporate Responsibility and Compliance

Financial transparency and regulatory compliance remain critical for Avinger.

Regulatory Compliance FDA Interactions Audit Compliance
100% regulatory adherence 13 FDA communication instances Zero major compliance violations
Sustainable Healthcare Innovation

Avinger's commitment to sustainable medical technology development continues in 2024.

  • Reducing surgical intervention complexity
  • Developing cost-effective treatment methods
  • Enhancing patient recovery processes

DCF model

Avinger, Inc. (AVGR) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.